[Figure: see text] It is assumed that high lipid profile (HLP) causes chronic systemic inflammation, which ultimately leads to inflammatory diseases and cancers. The aim of the study was to investigate the serum concentration of proinflammatory/tumor markers of interleukin-17 (IL-17), carcinoembryonic antigen (CEA), and prostate-specific antigen (PSA) in HLP. HLP cases [F/M: 11/17 triglyceride (TG) >200 mg/dL, high-density lipoprotein (HDL) <50 mg/dL for females and HDL <40 mg/dL for males] and controls (F/M: 12/15, TG <200 mg/dL) were included. The volunteers with diabetes, high blood pressure, infection, cancer, inflammation, smoking addiction, drug consumption, and pregnancy were excluded. Serum TG, cholesterol, HDL and low-density lipoprotein were measured by routine biochemical procedures. The serum levels of IL-17, CEA, and PSA (only in men) were determined by enzyme-linked immunosorbent assay (ELISA). Independent samples t-test was used to compare the data in 2 groups and association between the variables tested by Pearson correlation. IL-17 in HLP group was statistically higher compared with the controls (3.43 ± 0.5 versus 2.28 ± 0.3 pg/mL, P < 0.001). The serum levels of CEA and PSA were not different in the HLP and controls. There was also a statistically positive linear association between TG and IL-17. In conclusion, abnormal high concentration of HLP and IL-17 could be a pathological condition and may cause to increase the chronic systemic inflammation and inflammatory diseases.
Keywords: carcinoembryonic antigen; high lipid profile; interleukin-17; prostate-specific antigen.